BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 42.0
(5.0%)
JPY 42.0
(5.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.15 Billion JPY | -21.47% |
| 2022 | 1.47 Billion JPY | -1.19% |
| 2021 | 1.48 Billion JPY | -14.19% |
| 2020 | 1.73 Billion JPY | -5.45% |
| 2019 | 1.83 Billion JPY | 4.77% |
| 2018 | 1.75 Billion JPY | 9.35% |
| 2017 | 1.6 Billion JPY | 43.17% |
| 2016 | 1.11 Billion JPY | 7.56% |
| 2015 | 1.03 Billion JPY | 90.0% |
| 2014 | 547.19 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 326.99 Million JPY | 57.34% |
| 2023 Q2 | 257.15 Million JPY | -12.37% |
| 2023 Q1 | 293.44 Million JPY | 18.27% |
| 2023 Q3 | 396.62 Million JPY | 54.23% |
| 2023 FY | 1.15 Billion JPY | -21.47% |
| 2023 Q4 | 207.82 Million JPY | -47.6% |
| 2022 Q4 | 248.12 Million JPY | -40.51% |
| 2022 Q3 | 417.11 Million JPY | 60.62% |
| 2022 FY | 1.47 Billion JPY | -1.19% |
| 2022 Q2 | 259.69 Million JPY | -52.39% |
| 2022 Q1 | 545.5 Million JPY | 31.71% |
| 2021 Q3 | 352.29 Million JPY | 10.46% |
| 2021 Q1 | 402.73 Million JPY | -9.07% |
| 2021 Q4 | 414.15 Million JPY | 17.56% |
| 2021 Q2 | 318.93 Million JPY | -20.81% |
| 2021 FY | 1.48 Billion JPY | -14.19% |
| 2020 Q4 | 442.91 Million JPY | -14.52% |
| 2020 FY | 1.73 Billion JPY | -5.45% |
| 2020 Q1 | 409.13 Million JPY | -19.36% |
| 2020 Q2 | 363.95 Million JPY | -11.04% |
| 2020 Q3 | 518.15 Million JPY | 42.37% |
| 2019 Q2 | 421.22 Million JPY | -0.64% |
| 2019 Q4 | 507.35 Million JPY | 5.34% |
| 2019 Q1 | 423.95 Million JPY | 9.8% |
| 2019 Q3 | 481.65 Million JPY | 14.35% |
| 2019 FY | 1.83 Billion JPY | 4.77% |
| 2018 FY | 1.75 Billion JPY | 9.35% |
| 2018 Q4 | 386.12 Million JPY | -16.56% |
| 2018 Q3 | 462.74 Million JPY | 4.17% |
| 2018 Q2 | 444.23 Million JPY | -2.91% |
| 2018 Q1 | 457.55 Million JPY | 7.69% |
| 2017 Q1 | 264.87 Million JPY | -35.5% |
| 2017 Q2 | 425.78 Million JPY | 60.75% |
| 2017 Q3 | 485.44 Million JPY | 14.01% |
| 2017 Q4 | 424.86 Million JPY | -12.48% |
| 2017 FY | 1.6 Billion JPY | 43.17% |
| 2016 FY | 1.11 Billion JPY | 7.56% |
| 2016 Q3 | 234.64 Million JPY | -17.17% |
| 2016 Q2 | 283.28 Million JPY | 49.35% |
| 2016 Q1 | 189.68 Million JPY | -11.32% |
| 2016 Q4 | 410.64 Million JPY | 75.01% |
| 2015 FY | 1.03 Billion JPY | 90.0% |
| 2015 Q4 | 213.9 Million JPY | 11.32% |
| 2015 Q3 | 192.14 Million JPY | -41.74% |
| 2015 Q1 | 303.79 Million JPY | 0.0% |
| 2015 Q2 | 329.8 Million JPY | 8.56% |
| 2014 FY | 547.19 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 10.1% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -100.192% |
| GNI Group Ltd. | 9.32 Billion JPY | 87.613% |
| Linical Co., Ltd. | 2.7 Billion JPY | 57.314% |
| Trans Genic Inc. | 2.15 Billion JPY | 46.536% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 22.561% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 62.399% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 37.816% |
| AnGes, Inc. | 8.9 Billion JPY | 87.029% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -22.443% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 93.983% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -179.604% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -18.39% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 55.026% |
| CanBas Co., Ltd. | 278 Million JPY | -315.373% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -1.157% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 36.481% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 27.998% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 51.36% |
| PeptiDream Inc. | 9.68 Billion JPY | 88.08% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 41.103% |
| Ribomic Inc. | 1.1 Billion JPY | -4.436% |
| SanBio Company Limited | 4.53 Billion JPY | 74.56% |
| Healios K.K. | 3.48 Billion JPY | 66.884% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 13.468% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 17.722% |
| StemRIM | 2.07 Billion JPY | 44.377% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 41.19% |
| FunPep Company Limited | 313.82 Million JPY | -267.961% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -20.535% |
| Stella Pharma Corporation | 963.98 Million JPY | -19.788% |
| TMS Co., Ltd. | 943.25 Million JPY | -22.421% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -5.944% |
| Cuorips Inc. | 598.11 Million JPY | -93.062% |
| K Pharma,Inc. | 543.94 Million JPY | -112.291% |
| Takara Bio Inc. | 23.9 Billion JPY | 95.169% |
| ReproCELL Incorporated | 1.51 Billion JPY | 23.73% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 2.471% |
| StemCell Institute Inc. | 1.16 Billion JPY | 0.635% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 24.144% |
| CellSeed Inc. | 804.93 Million JPY | -43.458% |